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Natural Killer cells are large granular lymphocytes which take an important role in the 
immune control of cells with viral infection, mutations or cells coated with antibodies. 
Traditionally NK cells were believed to be part of the innate immune system. Over the last 
years, however, it has been shown that NK cells possess adaptive features as well. In 
humans NK cells with those adaptive features have been described in persons with a 
positive CMV-serostatus. Furthermore NK cells play an important role in patients 
undergoing allogeneic stem cell transplantation, most importantly for the control of 
infections and protection from relapse. With CMV and NK cells both playing an important in 
allogenic stem cell transplantation, this model seems to be perfect to study the impact of 
CMV on the generation of adaptive NK cells as well as the clinical impact of adaptive NK 
cells.  
We studied the NK cell-CMV interaction with the use of adaptive NK cells derived from 
CMV-seropositive blood donors and in patients with CMV reactivation after allogeneic stem 
cell transplantation. Adaptive NK cells derived from CMV-seropositive donors showed a 
specific tuning of ex vivo effector functions by virus-derived peptides. By sequencing of the 
CMV UL40 gene in patients with CMV reactivation we could derive the respective peptide 
encoded for during CMV reactivation.  In those patients with CMV-reactivation we were 
able to show that the generation of certain NK cell populations expressing the NKG2C-
receptor is influenced by the CMV-peptide polymorphism. For example the change of one 
amino acid (VMAPRTLIL to VMAPRTLFL) was able to trigger a difference in the generation 
of NK cell populations with FACS-defined cell profiles. 
Adaptive NK cells have strong effector functions and are thereby be thought to have anti-
leukemia functions as well. The link of adaptive NK cells to a better clinical outcome after 
allogeneic stem cell has been suggested by some investigators. Even though our data, 
because of the small sample size, just give a hint into this direction, the therapeutic use of 
adaptive NK cells in patients with hematologic malignancy could certainly play an important 
role in the future. 
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Natürliche Killerzellen sind große granuläre Lymphozyten welche eine wichtige Rolle in der 
Immunantwort auf Zellen mit Virusinfektion, Mutationen oder antikörper-bedeckte Zellen 
besitzen. Typischerweise werden NK-Zellen dem angeborenen Immunsystem 
zugeschrieben. In den letzten Jahren hat sich allerdings herausgestellt, dass NK-Zellen 
auch adaptive Eigenschaften besitzen. In Menschen sind adaptive NK-Zellen vor allen 
Dingen in Personen mit positivem CMV-Serostatus beschrieben worden. NK-Zellen spielen 
außerdem eine wichtige Rolle in Patienten welche eine allogene Stammzelltransplantation 
erhalten, vor allem zum Schutz vor Infektionen und einem Rezidiv der Grunderkrankung. 
Da sowohl CMV als auch NK-Zellen eine wichtige Rolle in der allogenen 
Stammzelltransplantation spielen, eignet sich diese als gutes Modell zur Untersuchung des 
Einflussen von CMV auf die Generation von adaptiven NK-Zellen, als auch zur 
Untersuchung der klinischen Relevanz adaptiver NK-Zellen. 
Wir haben die NK-Zell-CMV-Interaktion mithilfe von adaptiven NK-Zellen von gesunden 
CMV-seropostivien Blutspendern und innerhalb von Patienten mit CMV-Reaktivierung nach 
Stammzelltransplantation untersucht. Adaptive NK-Zellen von CMV-seropositiven 
Spendern zeigten dabei eine präzise Regulierung ihrer Effektor-Aktivitäten durch 
spezifische Virus-Peptide. Durch die Sequenzierung des CMV UL40-Gens in Patienten mit 
CMV-Reaktivierung konnten wir auf das jeweilig enkodierte Peptid während CMV-
Reaktivierung rückschließen. In dieser Patientenkohorte mit CMV-Reaktivierung konnten 
wir zeigen, dass die Generation spezifischer NKG2C-positiver NK-Zell-Populationen durch 
den CMV-Polymorphismus beeinflusst wird. Zum Beispiel konnte der Austausch von nur 
einer Aminosäure (VMAPRTLIL zu VMAPRTLFL) eine unterschiedliche Generation von 
NK-Zell-Populationen, definiert durch das durchflusszytometrische Zell-Profil, verursachen. 
Adaptive NK-Zellen haben starke Effektor-Funktionen, weswegen ihnen auch anti-
Leukämie-Effekte zugeschrieben werden. Die Korrelation von adaptiven NK-Zellen mit 
klinischen Variablen nach allogener Stammzelltransplantation ist von verschiedenen 
Autoren beschrieben worden. Auch wenn unsere Daten, vor allem aufgrund der kleinen 
Probenzahl, nur einen kleinen Hinweis in diese Richtung geben, könnte die therapeutische 
Nutzung von adaptiven NK-Zellen in Patienten mit hämatologischer Grunderkrankung in 
Zukunft sicherlich eine wichtige Rolle spielen. 
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1.1 NK cells 
 
Natural Killer cells are large granular lymphocytes which are important for the detection 
and control of cells with viral infections, spontaneous mutations1 and cells coated with 
antibodies2. They possess a sophisticated system of activation and inhibitory receptors, 
which specifically recognize changes on cell surfaces and in their milieu. Very importantly, 
they not only detect the presence of molecules signaling danger via activating receptors, 
but can also sense the loss of self-molecules expressed constitutively under normal 
circumstances, the latter also termed missing-self recognition3. After detecting an abnormal 
cell, NK cells display various effector functions. They were named Natural Killer cells, 
because they were able to spontaneously kill tumor cells4. They can kill other cells by 
releasing cytotoxic molecules from their granules, but they are also very potent producers 
of cytokines and chemokines, thereby taking part in an orchestrated immune response.5 
Traditionally they were believed to only be part of the innate immune system, possessing a 
static receptor repertoire and a short turnover time. In recent years, however, it has been 
shown, that NK cell populations display an unexpected diversity and that some also 
possess properties of adaptive immune cells, such as long-lasting imprinting of their 







1.1.1 Adaptive NK cells 
 
About 10 years ago, NK cells were shown to mediate a recall response in a mouse model 
of contact hypersensitivity with RAG-deficient mice, which lack B- and T-cells.7 
Subsequently, NK cells with adaptive properties have also been studied in other models, 
most extensively in infections with mouse cytomegalovirus (CMV).8 
Adaptive NK cells have also been described in humans. Guma et al. observed an 
expansion of NK cells expressing the activating receptor CD94/NKG2C in individuals with a 
positive CMV serostatus.9 Afterwards several adaptive features have been attributed to this 
subset. Those cells show a profound change in their cell surface receptor repertoire (e.g. 
CD2, NKG2A, KIRs) in comparison to canonical NK cells.9,10 In addition, epigenetic 
changes on focal and global levels have been shown. A demethylation of the IFNG locus 
CNS1, which directly parallels that of memory CD8 T cells and Th1 cells, showed an 
imprinted link to permanent functional changes.11 Also alterations in signaling adaptors and 
transcription factors characterize the NK cell expansion in individuals with positive CMV 
serostatus.12 This expanded NK cell subset possesses strong effector functions in 
response to selected stimuli, such as triggering via NKG2C or CD16 receptors.10,12,13 
Several investigators describe the expansion of this human NK cell subset in response to 
CMV14–16.  Which specific ligands or epitopes are involved in their generation, however, 
have only been speculated upon and probably involve redundant pathways induced by 









1.1.2 NK cell-MHC interactions and peptide specificity 
 
Analogous to T cells, the MHC system plays an important role in interactions of NK cells, 
but unlike T cells, NK cells do not possess the ability to express a rearranged receptor 
repertoire making use of recombination activated genes (RAG). Instead they have two 
RAG-independent systems of receptors which detect MHC molecules. One is represented 
by the highly diverse family of killer-cell immunoglobulin-like receptors (KIR), including 
activating and inhibitory members, whose main ligands are the classical MHC class I 
molecules HLA-B and HLA-C.19 The other system comprises more conserved lectin-like 
receptors, namely CD94/NKG2A and its activating counterpart CD94/NKG2C, which 
recognize the poorly polymorphic non-classical MHC class I molecule HLA-E.20 The 
inhibitory and activating functions of these receptors are carried mainly by different 
intracellular signaling domains, while the extracellular domains responsible for ligand 
binding are very similar. 
The inhibitory receptors recognizing their MHC ligands are important for a mechanism 
termed NK cell “licensing” or “education”.21,22 NK cells expressing MHC receptors which 
recognize self-ligands are rendered functionally active by this mechanism. Self-specific NK 
cells are tolerant under steady state but are highly competent in detecting and killing target 
cells which have downregulated surface MHC class I molecules upon infection or 
malignant transformation.3 
Also, for the activating receptors, diverse functions have been shown23. Different activating 
receptors (e.g. NKG2D, NKp30) have been shown to play a role in infection and tumor 
immunity.24–26 Owing to the constitutive engagement of inhibitory receptors, the 
orchestration by costimulation of several activating receptors is thought to play an 
important role in NK cell activation.27 
All cells containing a nucleus can express MHC I molecules. MHC class I molecules are 
loaded with short peptides derived from the cytoplasm (e.g. of a virus-infected cell) and 
these viral peptide-MHC class I complexes are recognized by the T cell receptor (TCR) 
expressed by CD8+ T cells, thereby initiating an immune response. 
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The role of peptides for NK cell-mediated recognition of MHC is now well recognized. It has 
been reported that the loading of different peptides on the MHC molecule can finely tune 
the activation and inhibition of some receptors28–30 and that NK cells also could detect 
virus-encoded peptides.31–33 Although the role of peptides in functionally shaping NK cell 
responses remains unclear, these findings provide another parallel to T cells and suggest 
that peptide-mediated recognition could be relevant for NK cell activation. 
 
1.2 Human cytomegalovirus 
 
Human CMV, also called Human Herpesvirus 5, is an enveloped double-stranded DNA 
virus which is a member of the of the Herpesviridae family. The name cytomegalovirus is 
derived from the enlargement of infected cells by viral inclusion bodies. Influenced by 
regional differences and age, the frequency of a positive CMV serostatus ranges from 60% 
to 100% of all individuals.34 A primary infection is still a very serious threat in prenatal 
condition, after birth or in immunodeficient individuals, but will otherwise only cause a mild, 
unspecific clinical phenotype. Like other herpesviruses, CMV has the ability to persist 
permanently inside its host in a latent state after primary infection. It will then only cause a 
pathogenic reactivation if the control by the host´s immune system is lost. Lots of different 
acquired and inherited immune defects can cause such reactivation, for example infection 
with HIV or immunosuppression after organ transplantation. During infection/reactivation 
nearly all organs can be affected. Typical complications are caused by CMV hepatitis, 
pneumonitis, colitis and retinitis. 
 
1.2.1 Immune evasion of CMV 
 
A big part of the CMV genome encodes for proteins important for immunoevasion, which 
could explain its ability to survive latently inside the host.34 As mentioned above, the 
recognition of peptide-MHC class I complexes is an important pathway of CD8+ T cell 
activation and CMV has to evade the MHC class I system. 
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CMV strains encode for many genes whose main function is related to the downregulation 
of HLA class I molecules by inhibiting different steps of HLA class I and peptide 
processing.35–38 One important immune evading mechanism by CMV is the inhibition of 
transporter associated with antigen presentation (TAP) dependent peptide loading by CMV 
US6.36  
On the other hand, NK cells can detect the downregulation of HLA class I, thus rendering 
these cells specialized for the defense against CMV.21,22 To avoid NK cell-mediated 
surveillance, CMV has evolved mechanisms to retain the expression of certain host HLA 
class I molecules39,40 or even codes for MHC class I-like molecules to mimic their functions 
as ligands for NK cell inhibitory receptors, as in the case of CMV glycoprotein UL18, which 
binds to LIR-1/ILT2.41 
CMV has also evolved strategies to evade immune recognition by the inhibitory NK cell 
receptor CD94/NKG2A. As mentioned previously, CD94/NKG2A binds the non-classical 
HLA class I molecule HLA-E, which is stabilized under steady state by signal peptides 
derived from other HLA class I molecules42, enabling NK cells to monitor the global HLA 
class I expression by NK cells, independent of the alleles expressed.20,43,44 Interestingly, 
the UL40 gene of CMV contains a sequence which is homologous to those encoding for 
the host signal peptides of HLA class I molecules.45 Those viral peptides are able to 
stabilize HLA-E and to inhibit NK cells expressing the inhibitory receptor CD94/NKG2A, 
thus serving as an additional immunoevasion strategy.33,45,46 On the other hand, a 
contribution to CMV control by NKG2C+ NK cells has been supported by a case report.47 It 
should also be mentioned that the homozygous deletions of the NKG2C locus is not such a 
rare event (~4% of all individuals) and that those individuals also have expansions of NK 
cells with phenotypic changes similar to those of individuals without NKG2C deletion.10 






1.2.2 CMV UL40 polymorphism 
 
Garrigue et al. and more recently Heatley et al. have shown that the CMV UL40 locus 
encoding for the signal peptide which stabilizes HLA-E is highly polymorphic.33,48,49 The 
latter group further tested those peptides for their ability to stabilize HLA-E in transfected 
cell lines and their ability to interact with both CD94/NKG2A and CD94/NKG2C by surface 
plasmon resonance analysis and observed profound differences between the peptides. 
The fact that some CMV strains possess sequences encoding for signal peptides which are 
non-functional suggests a selective pressure by the activating receptor CD94/NKG2C in 
CMV infections. Taken together this means that different CMV strains could have 
developed different strategies to adapt to particular conditions within the host. This would 
support a model in which, over a long period of time, coevolution led to a stalemate 
situation between CMV and the human immune system 
 
1.3 Allogeneic Hematopoietic stem cell transplantation (alloHSCT) 
 
The transplantation of hematopoietic stem cells was first successfully carried out in the late 
50s with bone marrow transplantation in syngeneic twins.50 With the discovery of the HLA 
system stem cell transplantation later became also possible from matched unrelated 
donors. Over the recent decades, the indications as well as patients who could be treated 
with this cell-based therapy gradually increased. The most common indications for an 
alloHSCT are nowadays hematologic malignancies, other hematologic disorders and 
inherited genetic defects involving the hematopoietic system. After initially being used 
mainly as a kind of supportive therapy to enable immune reconstitution after myeloablative 
radio-chemotherapy in leukemia, the importance of the graft itself in the treatment of 
malignancies is being emphasized nowadays. 
The discovery of the importance of the graft-vs-leukemia effect was the basis for the 
introduction of reduced-intensity conditioning, which made this therapy also available for 
patients with advanced age and morbidity51; it is now used more often than full 
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myeloablation. Patients undergoing alloHSCT still have a high mortality, caused by 
infections, graft-versus-host disease and relapse of the underlying disease. That is why 
supportive therapy (e.g. prophylactic immunosuppressive treatment of GvHD and graft 
rejection as well as preemptive/prophylactic treatment of infections) plays such a central 
role in patients undergoing stem cell transplantation. 
 
1.3.1 AlloHSCT and CMV 
 
During alloHSCT, the impaired immune response induced by conditioning as well as the 
treatment with immunosuppressive drugs facilitate CMV reactivation from its latent state 
and can cause a symptomatic infection of different organs. A preemptive strategy with 
regular monitoring of CMV-DNAemia by PCR and immediate treatment before clinical overt 
disease has reduced morbidity and mortality caused by CMV52 and is now the standard 
after alloHSCT. The highest risk factor for CMV DNAemia is a positive CMV serostatus of 
the recipient.53 About 50 to 60% of all CMV seropositive recipients will have detectable 
levels of CMV DNA after alloHSCT. Most reactivations happen within the first two months 
after transplantation, but they can even occur years after transplantation due to 
immunosuppressive treatment.54 
Even though the clinical impact of CMV in alloHSCT remains controversial, there is some 
data reporting a lower relapse rate in patients with early CMV reactivation, suggesting that 
CMV can promote an anti-leukemia effect.55,56 However, the overall survival rate, because 
of an increase in non-relapse mortality, remained unchanged. 
 
1.3.2 NK cells after alloHSCT 
 
NK cells are the first lymphocytes to recover after alloHSCT and might exert a beneficial 
effect as supported by data showing that NK cells can display both anti-tumor as well as 
anti-viral responses, while not causing or even protecting from GvHD.57,58 Indeed, several 
studies have linked different NK cell responses to an improved clinical outcome.  
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Patients with an early NK cell reconstitution have an improved survival rate.59 Moreover, 
patients receiving a graft with NK cells having an HLA-matched KIR and thereby having the 
ability of NK cell functional maturation by licensing show a strongly improved survival.60,61 
Last but not least, several studies investigating cell-based therapies with NK cell infusions 
have also shown some promising results.62–65 
The important role of NK cells after alloHSCT and the profound change of certain NK cell 
populations in CMV seropositive healthy individuals led to studies which showed that NK 
cells are also shaped by CMV reactivation after alloHSCT.17,66 Like CMV seropositive 
individuals, also patients with CMV reactivation showed an expansion of NK cells 
expressing the activating receptor CD94/NKG2C, an NK cell subset displaying higher 
functional capacities. Two recent studies tried to link the expansion of this NK cell subset to 
a clinical outcome.67,68 The results, however, were contradictory. While one group 
observed a reduced relapse rate in patients with CMV reactivation attributed to an increase 
of expanded NK cells, the other group observed an increased relapse rate in patients with 
NK cells displaying an adaptive phenotype. The authors of the second study discuss the 
differences found and attributed them to a different source of stem cells (peripheral HSCT 
against umbilical cord stem cell transplantation), as well as a longer follow-up during their 
study (with mostly protection from early relapse found in the first study). Also the time of 
the assessment of the NK cell phenotype is different between the two studies, with 6 
months after transplantation in the first study and 9 to 12 months after transplantation in the 
second study. One should note that due to early mortality a substantial part of patients also 




Several receptor affinity studies have shown that different signal peptides bound to the 
non-classical MHC class I molecule HLA-E strongly influence the binding to the receptors 
CD94/NKG2A and CD94/NKG2C.20,33 As previously outlined, the gene locus in CMV which 
carries the sequence for this signal peptide seems to be highly polymorphic.33 
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 It remains unknown whether the influence on the receptor-ligand interaction between HLA-
E and the activating receptor CD94/NKG2C has an impact on functionality or even the 
generation of adaptive NK cells. If this should be the case, then different CMV strains 
would shape the CD94/NKG2C expansion of NK cells differently.  
To show a relevance of this interaction in humans, patients undergoing alloHSCT serve as 
a good model. First of all, these patients have a high incidence of CMV reactivation, which 
is necessary to sequence the CMV UL40 gene. Secondly, NK cells play an important role 
in the clinical outcome after alloHSCT. Different interaction potentials of CMV encoded 
peptides could then influence the clinical outcome. 
Based on these premises, I formulated the hypothesis that different CMV UL40 
encoded peptides impact on shaping the repertoire and the functionality of adaptive 




In order to test this hypothesis in my thesis, I have investigated the following points: 
1. To analyze CMV UL40 signal peptide sequence polymorphism in our own cohort 
2. To classify different CMV UL40-derived peptides by functional impact on NK cells 
3. To investigate the impact of different CMV strains classified by functionality of CMV 
UL40 sequence on the shaping of adaptive NK cells in the patients 
4. To analyze the influence of adaptive NK cells on the clinical outcome and viral 


































All experimental procedures were performed with permission from the local ethics review 
board in Berlin, Germany. Patients and blood donors who participated in this study gave 
written informed consent (Charite ethics committee approval EA1/1/169/14). Buffy coats 
from healthy blood donors were obtained from “Deutsches Rotes Kreuz Blutspendedienst 
Nord-Ost” in Dresden (EA1/149/12). All patients undergoing alloHSCT at the Hematology 
Department of the Charité Hospital between November 2014 and December 2015 were 
asked to participate in this study. 40ml of blood was drawn weekly after alloHSCT while on 
the transplantation ward and thereafter selected patients were monitored at outpatient 
clinics. The plasma samples used for the qPCR monitoring of CMV copy numbers were 
obtained from the department of laboratory diagnostics (Labor Berlin GmbH) and used for 
CMV PCR and sequencing. Patient characteristics are summarized in Table 1. 
Patients treated with a myeloablative regimen received cyclophosphamide on two 
consecutive days (Cy; 60 mg/kg/d) and 6 x 2-Gy total body irradiation (TBI). In most cases 
patients with non-myeloablative conditioning were treated with fludarabin (6 x 30 mg/m²) 
and busulfan (2 x 4 mg/kg), but also different regimens were used. All patients were treated 
with antithymocyte globulin (ATG) before alloHSCT, either with 3x10 mg/kg or with 4x10 
mg/kg. Prophylaxis of aGvHD (acute Graft versus host disease) contained cyclosporine A 
(CSA) adjusted to blood levels and either methotrexate (MTX; 15 mg/m² at day 1 and 





The patients were monitored weekly for CMV after alloHSCT and less stringently at later 
stages in the outpatient clinic. The CMV copy number was monitored by qPCR and 
treatment was initiated if it exceeded 2000 copies/ ml. Patients were most commonly 
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2.2.1 Nested PCR and Sanger sequencing 
 
DNA from plasma during CMV reactivation was isolated using the QIAamp® DNA micro kit 
(Qiagen) in accordance with the manufacturer’s instructions. For the nested PCR, the 
following primers were used: 
Outer PCR forward: 5’-GGCTCTGTCTCGTCGTCATT-3’ 
Outer PCR reverse: 5’-TAAGGGCACTCGTGAGGATG-3’ 
Outer PCR product : 792 base pair length 
Inner PCR forward:  5’-CAACAGTCGGCAGAATGAAC-3’ 
Inner PCR reverse:  5’-CTGGAACACGAGCGGACATA-3’ 
Inner PCR product: 200 base pair length 
Table 2 shows the reaction mix and cycler settings used for the nested PCR and Figure 2 
shows an exemplary picture of a gel after electrophoresis of PCR products and Gene Ruler 
1kb plus ladder (Thermo Fisher Scientific). 
We had to adjust the settings of the nested PCR during the experiments because of 
contamination and subsequent amplification with an overcycled PCR product, producing a 
smear in the gel electrophoresis. At first, we used Platinum® Taq DNA Polymerase, Primer 
annealing temperature of 58°C for inner and outer PCR as well as 35 cycles instead of 30 
for the inner and outer PCR. 
For most of the PCR reaction, we then used AccuPrime™ Taq DNA Polymerase, high 
fidelity (ThermoFisher scientific) and the settings in Table 2. 
The product of the nested PCR was sent to commercially available Sanger sequencing 
with the reverse primer of the inner PCR (Mix2Seq by Eurofins genomics).  
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Amplified PCR products from some patients repeatedly showed bad quality in Sanger 
sequencing, which we were able to attribute to a polymorphism at the end of the primer 
binding site (Figure 3). The quality in those samples could be improved by the use of a 
shorter reverse primer not containing the base which bound to the polymorphic site (Primer 
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Primer 1 Primer 2 
Figure 3: Low quality sequencing caused by polymorphism at the primer binding site. 
(A) Nucleotide sequences of primer binding site from the two different primers used 
and sequences of primer binding site from 4 patients with low quality sequencing 
results. (B) Sequencing raw data of 4 patients with low quality sequencing results and 






2.2.2 Cloning of PCR products 
 
Inner PCR products for cloning were purified by the use of the QIAquick® PCR purification 
Kit (Quiagen) in accordance with the manufacturer’s instructions. Purified PCR products 
were poly-A tailed with the following reaction mix by incubation for 30 minutes at 70°C: 
4.4µl purified PCR product, 2µl 5xgoTaq buffer (Promega), 0.6 µl 25mM MgCl2 (Promega), 
4µl dATP (0.5m; NewEngland Biolabs), 1µl goTaq polymerase (Promega) 
The poly-A-tailed PCR products were then roughly quantified on an agarose gel with the 
use of Image Lab (Bio Rad) as software and the GeneRuler 1 kb DNA Ladder 
(ThermoFisher Scientific) as reference. Cloning into a vector and transformation into 
competent E. coli (JM109) was performed with the use of the pGEM®-T Easy Vector 
Systems kit (Promega) according to the manufacturer’s instruction with a molar ratio of 
PCR product to plasmid of 3:1 or 1:1. 
For the transformation SOC medium (ThermoFisher Scientific) was used and transformed 
cells were plated on agar plates (LB-Agar capsules MP biomedicals according to 
instructions) containing Ampicillin (100µg/ml), X-Gal (40mg/ml) and IPTG (1M). After 
incubation over night at 37°C colonies with the plasmid containing the PCR product could 
be detected by white/blue screening. Twelve white colonies per PCR product were picked 
and transferred into LB-Medium (LB-Medium capsules MP biomedicals according to the 
manufacturer’s instructions) and incubated shaking overnight at 37°C. Plasmid DNA was 
then purified with the use of the NucleoSpin plasmid purification kit (Machery-Nagel) 
according to the manufacturer’s instructions. Afterwards the PCR product sequence was 
amplified with the inner PCR of the nested PCR (see 2.2.1) and Sanger sequencing was 







2.2.3 Sample preparation, cryopreservation and NK cell isolation 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples and 
buffy coats obtained from patients and healthy donors by density gradient centrifugation 
(Ficoll-Paque PLUS, GE Healthcare Life Sciences).  
Cells were stored in liquid nitrogen in FCS supplemented with 10% DMSO or directly used 
for further experiments. After thawing of stored cells, they were rested in complete medium 
(RPMI1640 containing glutamine and supplemented with 10% FBS, 20 μM β-
mercaptoethanol, and 100 U/mL Penicillin-Streptomycin; all Thermo Fisher) at 37°C 
overnight before further use. 
For the use of NK cells in the stimulation assay, CMV seropositive donors were screened 
with FACS for an expanded phenotype according to Hammer et al.69 Before freezing, 
CD56+ cells were enriched by Magnetic cell separation using CD56 MicroBeads (human, 
Miltenyi) in an AutoMACS in accordance with the manufacturer’s instructions. Cells were 
cryopreserved in FBS containing 10% DMSO. 
 
2.2.4 Antibodies and flow cytometry 
 
Table 3 shows all antibodies used. All samples were stained with a Live/Dead viability dye. 
Intranuclear stainings were performed using the FOXP3 fix/perm buffer set 
(eBioscience™). For the intracellular staining of cytokines in the stimulation assay, cells 
were permeabilized with BD FACS™ Permeabilizing Solution 2 (BD Biosciences) The 
samples were acquired with a Fortessa 15 color flow cytometer (BD Biosciences) and 






2.2.5 Cell lines 
 
For the experiments, two different tumor cell lines were used. The human erythroleukemia 
cell line K562 transfected with HLA-E (K562/E) and the mouse lymphoma cell line RMA-S 
transfected with HLA-E (RMA-S/E). Both cell lines were maintained in complete medium. 
For selection of transfectants K562/E were supplemented with the antibiotic G418 
(Invivogen) at a concentration am 1mg/ml and RMA-S/E with Hygromycin B (Invivogen) at 
a concentration of 400µg/ml. 
 
2.2.6 Testing of HLA-E stabilization 
 
RMA-S/E transfectants with a cell concentration of 1x10e6/ml were pulsed with different 
peptides (synthesized by Peptides & Elephants GmbH) overnight at 300µM concentration 
in Gibco™ Opti-MEM™ I Reduced Serum Medium (ThermoFisher scientific supplemented 
with penicillin and streptomycin). The cells were then washed and stained with HLA-E PE-
Cy7 (clone 3D12, BioLegend), viability dye APC-eFluor780 (eBioscience) and FcR block 












Antigen(clone) dye manufacturer 
viability Zombie Aqua™ BioLegend 
viability APC-eFluor780 eBioscience 
CD14(61D3) BV510 BioLegend 
CD19(HIB19) BV510 BioLegend 
CD56 (HCD56) PE-Dazzle594 BioLegend 
CD3 (UCHT1) PE-Cy5 BioLegend 
CD57 (TBO1) Purified eBioscience 
NKG2A (REA110) PE-Vio770 Miltenyi 
NKG2A (REA110) Biotin Miltenyi 
NKG2C (REA205) PE Miltenyi 
CD2 (RPA-2.10) PerCP-Cy5.5 BioLegend 
LIR1α (HP-F1) APC eBioscience 
CD7 (M-T701) BV786 BD Biosciences 
Siglec-7 (REA214) APC-Vio770 Miltenyi 
FcεRIγ (polyclonal) FITC Merck 
Ki-67 (Ki-67) Alexa Fluor 700 BioLegend 
αIgM (RMM-1) for CD57 BV605 Biolegend 
Mouse FcR block(2.4G2) - DRFZ (in house) 
HLA-E (3D12) PE-Cy7 BioLegend 
Streptavidin BV785 BioLegend 
αCD107a (eBioH4A3) Alexa Fluor 488 eBioscience 
TNFα (Mab11) BV605 BioLegend 
IFN-γ (45-15) PE-Vio770 Miltenyi 








2.2.7 Stimulation of PBMCs from healthy donors 
 
K562/E transfectants were pulsed with different peptides as described for RMA-S/E. 
Frozen CD56+ cells from CMV seropositive donors with an NK cell expanded phenotype 
were thawed as previously described, sorted for viable CD3- CD56+ NK cells by the cell 
sorter staff at the DRFZ at a FACS BD ARIA or ARIAII and afterwards rested overnight in 
complete medium. Peptide pulsed K562/E and rested NK cells were washed once and then 
co-cultured at an effector:target ratio of 2:1 in serum-free Opti-MEM™ medium with 
peptides supplemented at a concentration of 300µM. For the assessment of degranulation, 
αCD107a (eBioH4A3, eBioscience) was added before starting the stimulation. The 
stimulation was started by centrifugation at 30g for 3 minutes. After one hour GolgiPlug™ 
and GolgiStop™ (both BD biosciences, containing Brefeldin A and Monensin) were added 
for the assessment of intracellular cytokines. Stimulation was stopped at 6 hours total time. 
Cells were washed once, stained for cell surface markers and intracellular cytokines before 
analysis and fixated with paraformaldehyde 2% before analysis with a FACS BD Fortessa. 
 
2.2.8 Statistical Analysis 
 
Statistical analysis was performed with Graph Pad Prism® Version 5. Categorical data 
analysis was performed by Fisher´s test for 2 variables and the Chi square test for 
comparison of more than 2 variables. For comparison of continuous data (FACS data) 
between two groups, the Mann-Whitney U test was used. Regression analysis was also 










3.1 Intra- and interhost variability of CMV UL40 sequences encoding for leader 
peptides 
 
Previous analysis of the UL40 sequence encoding for HLA-E stabilizing peptides derived 
from a limited number of HCMV strains has already indicated that this sequence is highly 
polymorphic in patients with CMV reactivation33. To assess the influence of CMV strains 
encoding for different leader peptides on NK cell phenotype and functionality, we first had 
to sequence CMV UL40 in our own cohort of patients with CMV reactivation, which we 
succeeded in 34 patients. (Figure 4) Interestingly, the analysis of the Sanger sequence 
data showed double peaks inside the sequence encoding for the leader peptides in 7 of 34 
patients with CMV reactivation, which is not surprising, as intrahost variability of CMV has 
already been described.48,49 By cloning PCR products into a vector, bacterial 
transformation and sequencing of single colonies, we were able to show that those double 
peaks were caused by different PCR products likely reflecting different CMV strains inside 
the host (Figure 1c). Inside the part of the CMV UL40 gene we sequenced, the sequence 
encoding for the leader peptide was much less conserved compared to the neighboring 
part of the sequence (Figure1a). Even though there were two other dimorphisms near the 
leader peptide sequence (V to L and C to S), polymorphisms with stronger changes of the 
amino acid properties (for example I to F at position 8 of the leader peptide) were only 
found inside the leader peptide sequence. 
Inside the leader peptide sequences, polymorphisms were found at all positions except 
position 7 (Figure 1b). The amino acid at Position 8, which is known to crucially influence 
the affinity of the HLA-E/peptide to NKG2/CD94 receptors70, showed the weakest 
conservation of all positions. 
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The cloning of the PCR products and sequencing of single transformed colonies of 
competent bacteria was also used to determine the quality of the sequencing data.  
Of 132 clones sequenced, which were derived from 12 different patient samples, only one 
clone showed a sequence not previously detected as peak in sanger sequencing of the 
not-cloned PCR product. Taken together with the fact that every PCR and sequencing 
been performed at least twice, this speaks for a high reproducibility of our sequencing data. 
 
3.2 Nonameric peptides derived from CMV UL40 sequences present in patient 
cohort differ in their ability to stabilize HLA-E 
 
The interaction between HLA-E-bound peptides and NKG2C should be influenced not only 
by the affinity, but also by the expression level of the ligand. That is why we tested the 
ability of the different nonameric peptides derived from polymorphic CMV UL40 sequences 
to stabilize HLA-E. Figure 5 shows the mean fluorescence intensity of an HLA-E-
transfected cell line pulsed with the different nonameric peptides at saturating 
concentrations. All peptides were able to increase the surface level of HLA-E compared to 
cells not pulsed with any peptide. The surface levels between the different peptides were, 
however, very different. Cells pulsed with the peptide VMGPRTLIL showed the lowest 
expression level of HLA-E. In their study Heatley et al.33 tested the ability of different 
peptides to stabilize HLA-E. The peptide VMGPRTLIL also induced the lowest expression 






























Figure 4: CMV UL40 encoding sequence shows high intra- and interhost variability.    (A) 
Translated sequences from 34 patients with CMV reactivation, sequence of nonameric 
leader peptide is marked with frame (B) Sequence logo displaying the conservation of the 
nonameric peptide (C) Sanger sequencing raw data from one patient with CMV intrahost 



























Figure 5: CMV UL40-derived peptides differ in their ability to stabilize HLA-E. (A) 
Representative FACS data showing the expression of HLA-E on RMA-S/E cells after 





3.3 UL40-derived peptides differently activate NK cells and NKG2A+ NK cells 
respond more sensitively than NKG2C+ NK cells 
 
In order to compare the NK cell properties of patients infected with different CMV strains, 
grouping of the different peptides according to the functional properties seemed necessary, 
because many different peptides (we detected CMV strains encoding for 21 different 
peptides in 34 patients) would have made a further comparison of the NK cell properties 
between the patients rather difficult. To do so we used an NK cell stimulation assay. NK 
cells from CMV-seropositive healthy donors with an expanded phenotype were stimulated 
by an HLA-E-expressing cell line (human erythroleukemia cell line K562 transfected to 
express HLA-E) which had been pulsed by the different nonameric peptides. It is well-know 
that K562 without transfection of HLA-E already causes a cytotoxic response of NK cells.71 
This baseline stimulation of NK cells makes it possible to measure the inhibition of 
NKG2A+ NK-cells (decrease of the baseline effector functions) and the activation of 
NKG2C+ NK-cells (further increase of the baseline effector functions) by peptide-pulsed 
HLA-E-transfected K562 cells at the same time. By determining the response by FACS-
measurement of different effector functions (Figure 6A+B) we could see peptide 
dependent differences in the activation of NKG2C+ NK cells and the inhibition of NKG2A+ 
NK cells (Figure 6C+D). As expected, the activation of NKG2C+ NK cells and inhibition of 
NKG2A+ NK cells negatively correlate with each other (Figure 6E) and one can also 
observe the different threshold of the activation markers 
(CCL3<CD107a<TNFalpha≤IFNgamma), which was previously defined by other 
investigators.72 It is known that NKG2A has a higher affinity to the HLA-E/peptide complex 
than NKG2C73 and accordingly, our data suggests a higher sensitivity of NKG2A to peptide 
changes than NKG2C. For example, NKG2A+ NK cells stimulated with VMAPRTLIL were 
already fully inhibited showing no effector functions, which was the case for stimulation with 
VMAPRTLFL as well. NKG2C+ NK cells could still respond to subtle peptide changes (e.g. 
much stronger effector functions with VMAPRTLFL than with VMAPRTLIL), making those 
cells more peptide-specific, at least in our model with saturated peptide doses. The peptide 
which displayed the strongest activation of NKG2C+ NK cells, VMAPRTLFL, is already 
known to have the strongest affinity to this receptor compared to other peptides.73,74 
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Peptides with relevant amino acid changes at position 5 (R to W or Q) or 6 (T to N or I), 
which are known to be important for the interaction of the peptide with the CD94/NKG2 
receptors75, showed the lowest activation and inhibition of NKG2C+ and NKG2A+ NK cells. 
The peptide VMGPRTLIL, which showed the weakest stabilization of HLA-E, also showed 
a comparably low potential to activate and inhibit NK cells. As previously outlined, I wanted 
to simplify the data and group the different peptides in order to use this data for the 
analysis of the influence of different CMV strains on the NK cells in patients undergoing 
alloHSCT. Based on our data, the peptide sequences and previous affinity studies 
available33, I classified the peptides into three categories (Table 4). 
Of course, those groups are not completely homogeneous, e.g. some of the peptides 
inside the intermediately interacting group also showed a slightly lower activation and 
inhibition potential. Also, the grouping is influenced more by the differences in the 
activation of NKG2C+ NK cells, as there was no difference for VMAPRTLFL in NKG2A+ 





















































































Figure 6: CMV UL40 derived peptides show different interaction potentials with NK cells and NKG2A+ 
NK cells are more sensitive than NKG2C+ NK cells (A) Representative FACS plot showing  expression 
of different activation markers after incubation with peptide-pulsed K562/E. Gated on NKG2C+ NK 
cells and (B) NKG2A+ NK cells. (C) Summary of data with NK cell stimulation assays from 6 different 
donors in 3 different experiments with mean and standard deviation of activation marker positive NK 
cells of NKG2C+ NK cells and (D) NKG2A+ NK cells. (E) Activation of NKG2C+ NK cells plotted 
against the Inhibition of NKG2A+ NK cells for the 15 different peptides tested and regression curve 
derived for a cumulative Gaussian distribution. The values represent the mean of results from the six 
different donors. Result for stimulation without peptide is plotted at x=0;y=0                                                                                                                   
Activation: (activation with peptide - activation with no peptide) / activation with VMAPRTLFL    
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3.4 Expanded NKG2C+ NK cells in alloHSCT patients with CMV reactivation show a 
specific phenotype, which is influenced by CMV strains encoding for different 
leader peptides 
 
Out of the 34 patients with CMV reactivation and known sequence of the CMV UL 40 
leader peptide sequence we were able to analyze NK cells by FACS from 15 patients after 
CMV reactivation.  
We further tested 6 patients with Recipient and Donor CMV-negative serostatus (R-D-), 
which should not have been in contact with CMV, as a control for the general influence of 
CMV on NK cells (Table 5). The patients were grouped according to the different peptides 
encoded by CMV.  
One patient with an intermediately interacting peptide had a coinfection with a CMV strain 
encoding for LMAPRTLVL, which had not been tested, and one patient with the strongly 
interacting peptide VMAPRTLFL had a coinfection with a CMV strain encoding for the 
intermediately interacting peptide VMAPRTLLL. Two other patients had coinfection with 
other CMV strains, but both from the intermediate class (VMAPRTLIL + VMAPRTLLL and 
VMAPRTLLL + VMAPRTLVL). Figure 7A shows the distribution of the CMV strains 
encoding for the different peptides from the 15 patients. 
To assess the influence of different CMV strains on NK cells we applied markers which are 
typically associated with adaptive NK cells. Typically the NKG2C+ expansion is associated 
with an increased frequency of CD2+ cells and a decreased frequency of Siglec-7+, 
NKG2A+ and FcεR1γ+ inside the expanded cells.10,12,17,76 Figure 7B illustrates two 
examples; one is obtained from a patient with R-D- serostatus without expansion and the 
other from a patient with CMV reactivation and a very strong expansion of NKG2C+ NK 
cells showing the typical pattern of phenotypical markers.  
Patients with CMV reactivation exhibit the expected increase of NKG2C+ NK cells 
compared to Recipient/Donor serostatus negative patients (Figure 7C). The patient with 
the not/weakly interacting peptide VMAPRNLIL had a higher proportion of NKG2C+ NK 
cells than the patients with the strongly interacting peptide VMAPRTLFL, suggesting an 




By assessing typical markers of expanded NK cells inside the NKG2C+ and NKG2C- NK 
cell population and by considering the properties of the leader peptides encoded by 
different CMV strains, one can see which phenotypic changes are dependent on different 
peptides and NKG2C (Figure 7D). The frequency of Siglec-7+ cells was significantly lower 
in NKG2C+ and NKG2C- NK cells and showed no dependency on stronger interacting 
peptides, speaking for a NKG2C/peptide-independent induction of Siglec7 negativity. The 
frequency of CD2+ cells showed a trend towards higher frequency in NKG2C+ NK cells in 
patients with CMV reactivation, even though not significantly. As in the induction of Siglec-
7- NK cells by CMV, the induction of CD2+ NK cells seems to be not dependent on high-
affinity leader peptides encoded by CMV. 
There is a non-significant trend towards a lower frequency of NKG2A+ NK cells inside 
NKG2C+ NK cells in patients with CMV reactivation. In contrast to CD2 and Siglec-7 the 
two patients infected with CMV strains encoding for the strongly interacting peptide were in 
this case the ones with stronger selection of NKG2A- NK cells inside the NKG2C+ NK 
cells. They had a much lower frequency than the patient infected with the not/weakly 
interacting peptide. These findings and the absence of the effect in NKG2C- NK cells 
suggest a dependency of the selection of NKG2A- NK cells on the NKG2C-peptide 
interaction. 
This NKG2C-peptide dependent effect was even more pronounced for FcεR1γ, where the 
selection of FcεR1γ- NK cells was much stronger in the two patients with the strongly 
interacting peptide and only present within NKG2C+ NK cell populations.  
To better define expanded NK cells, we assessed NK cells coexpressing all 3 markers in 
the typical combination (CD2+, NKG2A- and Siglec7-), which were significantly increased 
inside the NKG2C+ and also inside the NKG2C- population of NK cells (Figure 7E). 
NKG2C+ NK cells with this specific combination of markers were slightly higher in 
frequency within the patients infected with a CMV strain encoding for the strongly 
interacting peptide, suggesting a dependency on the NKG2C-peptide interaction driven by 
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CMV peptide sequence 
    Intermediately interacting 
        double peak 
    Strongly interacting 
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    Not/weakly interacting 
        double peak 












Peak viral load in cop/mL 






Table 5: Characteristics of patients with CMV reactivation and control patients with recipient 
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Figure 7: The infection of patients with CMV strains encoding for UL40-derived leader peptides with 
differing interaction potentials impacts on the phenotype of NK cells. (A) Distribution of CMV UL 40 
encoded leader peptides within the patients with FACS analysis of NK cells derived from Sanger 
sequencing. If the patient had a coinfection with another CMV strain, then both peptides were included. 
(B) Representative FACS plots of one patient with recipient/donor CMV negative serostatus (R-D-) and 
a patient with CMV reactivation and a very strong expansion of NKG2C+ NK cells displaying typical 
phenotypic changes. (C) Percentage of NKG2C+ NK cells from R-D- patients (n=6) and patients with 
CMV reactivation (n=15). (D) Expression of different phenotypic markers on NKG2C+ and NKG2C- NK 
cells comparing R-D- patients and patients with CMV reactivation. FcεR1γ+ NK cells are also 
compared between patients with an CMV strain encoding for a strongly interacting peptide (strong) and 
other patients with CMV reactivation (rest) (E) Comparison of NK cells with typical phenotypic 
coexpression pattern (CD2 positive; NKG2A negative; Siglec-7 negative) between patients with CMV 




3.5 NK cells with typical coexpression pattern contribute to the NKG2C+ NK cell 
expansion 
 
NK cells expressing the specific coexpression were the cells which contributed most to the 
expansion of NKG2C+ NK cells, when comparing R-D- patients and patients with CMV 
reactivation (Figure 8). Also, within the proportion of patients with CMV reactivation, a 
higher amount of CD2+, Siglec-7-, NKG2A- NK cells correlated with a higher overall size of 
the NKG2C+ NK cell expansion. 
The patients with the strongly interacting peptide showed a stronger selection of the 
phenotype in relation to the overall frequency of NKG2C+ NK cells compared to the 
not/weakly interacting peptide, which could mean that the peptides are more important for 


















Figure 8: NK cells with a specific coexpression pattern are responsible for NKG2C+ NK cell 
expansion. (A) Pie chart demonstrating the distribution of NKG2C+ NK cells (red and yellow) and 
NKG2C+ NK cells with specific coexpression pattern (red) in patients with CMV R-D- serostatus 
(n=6) and patients with CMV reactivation (n=15). Data used are the mean values from the different 
patient groups. (B) Correlation of NK cells displaying a specific coexpression pattern (CD2 
positive; NKG2A negative; Siglec-7 negative) with percentage of NKG2C+ NK cells within 




3.6 NK cell expansion correlates with time after transplantation, but not with the 
monocyte count 
 
The samples we obtained from our cohort were taken at different time points after 
transplantation. This was due to differing time periods of CMV reactivation after 
transplantation, but also due to the early mortality of patients in our cohort, which 
prevented further follow-up. Figure 9 shows the influence of the time post transplantation 
on the frequency of NKG2C+ NK cells. There is a significant correlation with the overall 
size of the expansion, but not with the phenotype of the expansion, defined by the 
coexpression pattern. The samples from the two patients with the strongly interacting 
peptide, however, were obtained from earlier and later time points compared to the patient 
with the weakly interacting peptide, which makes a bias caused by time dependency 
unlikely. 
Cichocki et al. have recently reported an association of higher monocyte counts with higher 
amount of NKG2C+ NK cells.67 However, in our cohort we did not observe a correlation 











Figure 9: Percentage of NKG2C+ NK cells correlates with the time after transplantation, but not 
with the monocyte count. (A) Correlation of time after transplantation with percentage of NKG2C+ 
NK cells and NK cells with specific coexpression pattern of phenotypic markers in patients with 






3.7 The adaptive phenotype of the NK cell expansion is associated with an 
improved clinical outcome 
 
After investigating the effect of the different peptide classes on the selection and the 
phenotype of the NKG2C+ NK cell expansion, we also wanted to know if the markers of 
expansion could have any impact on the clinical outcome in patients with CMV reactivation 
(Figure 10).  
The overall size of expanded NKG2C+ NK cells was not significantly higher in patients 
surviving without relapse, even though there was a trend towards a higher frequency of 
NKG2C+ NK cells. However, the patients which survived without relapse showed a 
significantly higher amount of NK cells coexpressing the typical markers of expanded NK 




















Figure 10: Patients surviving without relapse have a stronger induction of expanded NK cells. 
Comparison of percentage of NKG2C+ NK cells, specific coexpression pattern (CD2 positive; 
NKG2A negative; Siglec-7 negative) and FcεR1γ+ NK cells between patients that died later on or 




3.8 The stringency of monitoring CMV in alloHSCT patients has an impact on the 
strength of the reactivation, and expanded NK cells correlate with a lower peak 
viral load  
 
No correlation between the percentage of total NKG2C+ NK cells or of NKG2C+ displaying 
an adaptive phenotype with the peak viral load could be observed. (Figure 11A). 
Normally, the patients were monitored weekly by qPCR for CMV reactivation. Patients who 
were not monitored regularly had a delay of diagnosis and consequently a higher viral load 
(Figure 11B), probably because of a later initiation of antiviral treatment. In line with this, 
the time from last qPCR control to diagnosis correlated with the viral load. 
When selectively taking those patients into account who were monitored regularly and thus 
treated adequately, the percentage of NKG2C+ NK cells or of NKG2C+ displaying an 
adaptive phenotype correlated negatively with the viral load (Figure 11C). This means that 
patients with a strong CMV reactivation did not have a strong expansion of adaptive NK 
cells, suggesting that patients with a robust expansion of NKG2C+ NK cells or of NKG2C+ 
NK cells displaying an adaptive phenotype might be able to better control the virus, at least 

































Figure 11: Patients with a stronger NKG2C+ NK cell expansion have lower viral loads during CMV 
reactivation (A) Correlation of peak viral load during CMV reactivation with percentage of NKG2C+ NK 
cells and NK cells showing a specific coexpression pattern (CD2 positive; NKG2A negative; Siglec-7 
negative). All patients with FACS data and CMV > 2000 copies/ml were included (n=14) (B) 
Correlation of days from last negative CMV PCR to diagnosis with viral load. All patients with available 
data were included (n=31). Dashed line shows limit for inclusion for further analysis (only patients who 
were monitored weekly) (C) Correlation of peak viral load during CMV reactivation with percentage of 
NKG2C+ NK cells and NK cells showing a specific coexpression pattern (CD2 positive; NKG2A 








As mentioned before, it became more and more clear in recent years that defined NK cell 
subsets display adaptive properties. The best characterized adaptive NK cell subset in 
humans is composed of NKG2C+ cells, which expand in response to CMV 
infection/reactivation. 
Even though different receptor-ligand pairs have been shown to be potentially involved in 
mediating activation of NK cells by CMV infected cells, it is not known which interactions 
are most crucial for the development of adaptive NK cells and viral control. Probably there 
are several and also redundant pathways involved, which collectively lead to all the 
changes that are described for the NKG2C+ NK cell expansion. One should note that even 
NKG2C is dispensable for the expansion of adaptive NK cells10. 
Nevertheless, we chose to investigate the interaction of CMV and expanded NK cells by 
the axis of CMV UL40 encoded signal peptide/HLA-E and the NK cell receptor 
NKG2C/D94, because this receptor was the first to be described as being involved in 
human adaptive NK cells9, the interaction is extensively characterized on a molecular 
basis75 and it is the most frequent adaptive population in NK cells.10 
In contrast to other studies addressing this peptide-NKG2C interaction, we here, for the 







4.1 CMV UL 40 sequencing 
 
In a recent study33 Heatley et al. described the CMV UL40 gene polymorphism in a cohort 
of HSCT patients. The characterization of peptide polymorphism in our cohort is consistent 
with the results from their study. After repeatedly detecting double peaks in Sanger 
sequencing reads of some patients, we could show, by cloning of PCR products, that this 
event relates to the occurrence of mixed PCR products, likely reflecting mixed CMV 
sequences in vivo. 
About 20% of the patients from our cohort showed such mixed CMV sequences. Moreover, 
we have identified new UL40 sequences, further supporting the large diversity displayed by 
CMV strains at this site. The CMV strains we sequenced encoded most commonly for 
peptides with an intermediate interaction potential (e.g. VMAPRTLIL), suggesting an 
evolutionary advantage of these variants, probably caused by host immune pressure. 
The high frequency of mixed strain CMV infections seems somewhat unexpected, 
considering that CMV is a large DNA virus possessing a high fidelity DNA polymerase with 
3’-5’ exonuclease activity77. Recent deep sequencing studies on HMCV, however, have 
also shown such high intrahost variability, reaching an intrahost nucleotide diversity which 
is comparable to that of highly polymorphic RNA viruses, such as HIV.78 Possessing a 
proofreading DNA polymerase, the mechanisms of this high diversity are probably different 
from those in RNA viruses. This is supported by our observation that samples taken at 
different points in time, but from the same patients, almost exclusively showed the same 
sequencing result, speaking against short term spontaneous mutations as the most 
important mechanism. Combined with the fact that CMV is capable of DNA 
recombination79,80, the most reasonable explanation is therefore the occurrence of multiple 
strain infections. The occurrence of different CMV variants in one host could be considered 





If the human NK cells can have the activated NKG2C+ and the inhibited NKG2A+ NK cells, 
also different virus populations could produce peptides with different properties (e.g. in a 
patient acquiring a very strong expansion of NKG2C+ NK cells, a second virus population 
encoding for a peptide with a weaker interaction potential could be advantageous). One of 
our patients with a mixed strain infection and a strong NKG2C+ NK cell expansion showed 
only one sequence encoding for a weaker interacting peptide during a later second CMV 
reactivation, which could be an indication to support this hypothesis. 
 
4.2 HLA-E stabilization by different peptides 
 
The different peptides showed differences in their ability to stabilize HLA-E in a transfected 
cell line. Even though the analysis of our patient mainly cohort resulted in CMV UL40 
encoded peptides different from those found by Heatley et al.33, overlapping peptides were 
also tested, showing comparable results. Also, in our experimental setting, the peptide 
VMGPRTLIL was the peptide showing the weakest stabilization of HLA-E. Interestingly, the 
peptide VMGPRTLLL, which Heatley et al. did not test, induced a stronger expression of 
HLA-E. Other peptides with L instead of I at position 8 (e.g. VMAPRTLIL/VMAPRTLLL or 
VMAPRSLIL/VMAPRSLLL) showed no such big differences in the ability to induce HLA-E 
expression. With our data, it thus seems difficult to tell if there are certain positions of the 
peptide which are necessary for the stabilization of HLA-E, as combinations of several 
position changes can lead to differences in the ability to stabilize HLA-E. 
One should note that we only tested the ability of the different peptides, but not the virus 
itself, to stabilize HLA-E. As mentioned previously, CMV inhibits the TAP-dependent 
processing of peptides inside infected cells.36 To maintain the expression of the UL40-
derived signal peptide, the virus must provide a TAP-independent mechanism of peptide 
processing. In their study, Prod’homme et al.46 have nicely shown that this mechanism is 
facilitated by gpUL40 itself and that HLA-E stabilization is impaired without the N-terminus 
of the peptide. Probably also the sequence of the signal peptide itself could influence the 
processing, as the binding to the ER membrane or affinity to the signal peptide peptidase 
could be influenced by this sequence.46  
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With our model, it was not possible to determine the effect of the processing ability, 
because we already used the readily processed nonameric peptides. 
 
4.3 Influence of different peptides on activation and inhibition of NK cells 
 
We found different reactions of NK cells expressing certain NKG2-receptors, a possible 
(and strongly simplified) in vivo model is shown in Figure 12. 
More importantly, we found profound differences in the activation and inhibition of NK cells 
by the different peptides, showing that NKG2C+ NK cells are differentially activated by 
different peptides. Interestingly, most CMV strains found in our cohort encoded for peptides 
which were able to nearly completely inhibit the response of NKG2A+ NK cells, but just 
intermediately activate NKG2C+ NK cells. Figure 1 shows a possible model of the in vivo 
reaction of NK cells expressing certain NKG2/CD94 receptors. Still some patients were 
infected with virus strains encoding for peptides with other properties, which could suggest 
a superior immunoevasion of certain virus strains in specific host situations. As there is a 
considerable number of individuals with a homozygous NKG2C deletion (~4%)10, a virus 
strain encoding for the peptide with the strongest activation potential VMAPRTLFL could 
have better immunoevasion properties in those persons. We found strains encoding for this 
peptide in 2 out of 34 patients. Neither of the two patients had NKG2C deficiency. Certainly 
much more patients have to be assessed to show an immunoevasion advantage of specific 
CMV strains in specific patient subgroups. 
Our data shows that NK cells expressing the inhibitory receptor NKG2A are already 
maximally inhibited by stimulation with peptides which are recognized only with 
intermediate efficacy by NKG2C+ NK cells, suggesting that NKG2A might react more 
sensitively to HLA-E/peptide complexes. 
Indeed, the difference in the sensitivity of those receptors corresponds to the higher affinity 
of HLA-E/peptide complexes to NKG2A compared to NKG2C.73 
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NK cells have the ability to display effector functions, such as release of CCL2, IFNγ or 
TNFα and degranulation (CD107a) in response to combined engagement of different 
activating receptors. Fauriat et al.72 have previously determined the different thresholds of 
activation required to induce distinct effector functions in NK cells, e.g. 
CCL3<CD107a<TNFα<IFNγ, implying that induction of IFNγ is generally achieved only in 
the presence of multiple receptor engagement. Interestingly, our results show nearly similar 
thresholds in NKG2C+ NK cells when triggered via one single receptor (NKG2C) with 
peptides displaying different functional avidity. 
Indeed, degranulation and the production of the chemokine CCL3 could be easily induced 
in NKG2C+ NK cells even by intermediate peptides, while high production of the cytokines 
IFNγ and TNFα was achieved only in the presence of the high avidity peptide.  
In NKG2A+ NK cells, the baseline activation (activation without peptide) followed the same 
pattern as in NKG2C+ NK cells. While there were about 40% CCL3+ NK cells without any 
peptide, only about 6% were TNFα+. Not surprisingly, those markers with lower baseline 
activation are more easily inhibited to the full extent than those with higher baseline 
activations. Thus, the different threshold of inhibition of the different markers in NKG2A+ 
NK cells is in line with the threshold of activation of NKG2C+ NK cells (e.g. IFNγ has a high 
activation threshold in NKG2C+ NK cells, and baseline activation in NKG2A+ NK cells is 
fully inhibited already by lower affinity peptides). 
The molecular basis for the interaction of the HLA-E/peptide complex and NKG2/CD94 
receptors is well characterized.73–75 Positions 5 and 6 of the nonameric peptide are thought 
to be important for the interaction with CD94 and position 8 for the interaction with 
NKG2A/C. Our data supports this; peptides having changes at position 5 or 6, compared to 
the most common peptide VMAPRTLIL, are also those with the biggest change in 
activation and inhibition of the respective NK cells. One exception is given by a change 
from T to S at position 6, which had no influence. Changes at position 8 had a stronger 
influence on the activation of NKG2C+ NK cells, which seem to have the ability to be fine-
tuned by the polymorphism at position 8, while in NK cells expressing the high affinity 




One should note, that we tested the activation/inhibition of NK cells at saturated peptide 
concentrations and that with a lower availability of peptide or target cells (or a higher 
baseline activation), which all might be present in an in vivo setting, the inhibition of 
NKG2A+ NK cells could probably also be fine-tuned. 
We did not test the influence of a mixture of tumor cells pulsed with different peptides 
(which might be present in mixed strain infections) on the response of NK cells seen in 
some of our patients. Probably the mechanism of interaction between the different peptides 
would be more complicated than just being pure competition. Cassidy et al.29 suggest 






Figure 12: A speculative model which shows the immunoevasion of CMV by inhibition 












4.4 Analysis of NK cells from alloHSCT patients 
 
By analyzing phenotypic markers of NK cells in patients with known CMV UL40 leader 
peptide sequences, we could determine the influence of the encoded peptide on adaptive 
NKG2C+ NK cells. Even though we detected just a few patients with CMV strains encoding 
for peptides with highly different properties determined by our stimulation assay, the 
influences on some NK cell phenotypic markers were profound. 
In our data set, the marker with the highest sensitivity to detect an exposure to CMV was 
Siglec-7, which is, however, independent on the peptide-NKG2C axis, as a much lower 
frequency of Siglec-7+ NK cells was observed both, in NKG2C+ and NKG2C- NK cells and 
there was no influence of the peptide avidity on the frequency of Siglec-7- NK cells. This 
suggests that this effect is caused by a different pathway, perhaps involving the glycocalyx, 
which is targeted by Siglec-781 as well as CMV82. In line with these data, down-regulation 
of Siglec-7 is not a hallmark of CMV but can also be found in other viral infections83–85. Also 
interestingly, Siglec-7 modulates NK cell response to tumor cells,86 and it has been shown 
that T-ALL blasts could evade NK cell immunosurveillance by upregulation of Siglec-7 
ligands.87 Based on those facts, one could speculate that the lower frequency of Siglec-7 in 
patients with CMV reactivation could lead to a better immunosurveillance by NK cells.  
The costimulatory molecule CD2 was also found to be independent from the peptide-
NKG2C axis, and even though it is a marker associated with CMV-induced adaptive NK 
cells10, it did not reach significance in our small cohort in comparison of patients 
undergoing  or not undergoing reactivation with CMV.  
As the costimulatory molecule CD2, which is also typically expressed on T cells, and its 
ligand CD58, are involved in many cell-cell interactions88,89, it is not surprising, that the 
peptide-NKG2C axis does not lead to a specific induction. Perhaps there are more 
unspecific factors, e.g. inflammatory cytokines, involved in the induction of CD2 on NK 
cells. In line with this, Sun et al. have nicely shown the importance of IL-12 for the 
generation of adaptive NK cells in mouse cytomegalovirus.90 Most likely, some changes 
observed in human adaptive NK cells could be attributed to this axis of interaction. 
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The selection of NKG2A- NK cells inside the NKG2C+ NK cells was found to be influenced 
by the peptide-NKG2C axis, even though not as strongly as FcεRIγ- NK cells were. 
Because NKG2A has the same ligands as NKG2C, one might think that the effect is 
caused independently of NKG2C (NKG2A+ NK cells could be negatively selected, because 
they are inhibited by the peptide/HLA-E complex). The fact that NKG2C- NK cells seem to 
have a peptide-independent pattern of NKG2A frequency, with nearly similar frequencies of 
NKG2A+ NK cells in the patients with the strongly and the not/weakly interacting peptides 
(we did not observe a negative selection of NKG2A+ NK cell inside the NKG2C- NK cells 
influenced by the peptide/HLA-E complex). Our data is in line with the hypothesis that the 
engagement of the NKG2C receptor is necessary for the selection of NKG2A- cells. 
There was a very strong selection of FcεRIγ- NK cells within the NKG2C+ NK cells in the 
two patients with the strongly interacting peptide. Interestingly, some of our patients 
showed an accumulation of FcεRIγ- within NKG2C- NK cells, but not in those two with the 
strongly interacting peptide, where FcεRIγ- were confined to NKG2C+ ones. This shows 
that the peptide-NKG2C axis is not per se necessary for the induction of FcεRIγ- NK cells, 
but leads to a preferential accumulation of those cells in the NKG2C+ NK cell population. 
The change in the expression of the signaling adaptor FcεRIγ is thought to be a marker of 
a more profound epigenetic reprogramming of adaptive NK cells and it was suggested that 
signaling adaptor molecules in adaptive NK cells are responsible for functional 
differences.12 
Taken together, the influence of the peptide-NKG2C axis on NK cells is much more 
complicated than just being: higher affinity peptides mean more adaptive NK cells. It rather 
seems to be the following: different peptides mean adaptive NK cells with a different 
phenotype.  Adaptive NK cells can also be found in individuals with a deletion of the 
NKG2C locus and no influence of the peptide-NKG2C axis.10 One could sum up our 
findings as follows: The engagement of NKG2C+ NK cells by stronger interacting peptide 
makes it more likely for adaptive NK cells to accumulate inside the compartment of 




The profound induction of Siglec-7- NK cells within the whole population of NK cells in 
contrast to the mild induction of other markers in specific subsets shows that CMV does not 
just induce the generation of one adaptive, homogenous NK cell population, but does 
rather cause different changes in different cell population at the same time, this is very 
likely further complicated by the influence of spatiotemporal factors. Nevertheless, we 
found an influence of different peptides on the pattern of different markers within the 
different NK cell population, which can be considered as an adaptive feature of NK cells. 
One important limitation of our study is given low number of patients analyzed, thus not all 
conclusions drawn are based on statistically significant results, but still, it is very unlikely, 
that different CMV UL40-encoded peptides have no influence on NK cells. 
 
4.5 Other factors influencing the NK cell expansion 
 
In order to check for possible biases of our data, we tried to look for other factors, which 
could influence the frequency and phenotype of NKG2C+ NK cells. As mentioned above 
Cichocki et al. reported an association of higher monocyte counts with higher amount of 
NKG2C+ NK cells.67 We did not observe this correlation in our cohort, which is not 
surprising, as we examined a much smaller cohort, and the correlation that Cichocki et al. 
had observed, was not so strong (R²=0.29). One important limitation of our study is that the 
samples obtained for the analysis of the NK cell phenotype were not gathered from the 
same time points after transplantation, on the other hand, we were able to obtain samples 
from patients with early mortality, which could not be included in recent studies 
investigating the phenotypic properties of CMV-induced NK cells after alloHSCT.68 
The frequency of NKG2C+ NK cells correlated weakly with the time after transplantation, 
while no significant correlation could be observed with the amount of NK cells expressing 




Even though a bias of our data concerning the time after transplantation cannot be fully 
excluded, the fact that the samples from the two patients with the CMV strain encoding for 
the strongly interacting peptide were from very different time points, but still showed similar 
phenotypic changes, makes it extremely unlikely that our data for the peptide-specific 
phenotype induction is biased by time. 
 
4.6 Association of adaptive NK cells with improved clinical outcome 
 
It has been reported that CMV reactivation after alloHSCT can lead to a lower relapse rate 
of the underlying disease56. Given the important role of NK cells in alloHSCT, it could be 
possible that NK cells are involved in the mediation of this virus-versus-leukemia effect. 
Even though we have not found a lower relapse rate in patients with CMV reactivation in 
our small cohort, we wanted to look at the influence of the shaping of the NK cell repertoire 
by different CMV strains on the clinical outcome. 
Patients who survived and had no relapse showed NKG2C+ NK cells expressing markers 
associated with adaptive properties. The markers which have been shown to be influenced 
by the peptide-NKG2C axis (NKG2A-, FcεRIγ-) were also associated with a better clinical 
outcome. Interestingly, the two patients with the CMV UL40 encoded strongly interacting 
peptide also survived without relapse for at least 1 year. 
With just 15 patients included, it was of course not possible to perform a detailed 
multivariate survival analysis. There has not been any systematic follow-up of the patients, 
as the clinical data was obtained retrospectively.  
Nevertheless, our data gives a hint for some association of a specific NK cell phenotype 
with a better clinical outcome, which could also be influenced by certain CMV strains. As it 
has been shown that HLA-E is expressed by most leukemia cell lines and by some other 
tumor cell lines91, it is tempting to speculate that HLA-E recognition by NKG2C could be 




It is thought that malignant cells maintain the HLA-E expression to inhibit NK cell lysis 
through NKG2A and indeed some in vitro and in vivo data showing improved NK cell 
mediated lysis after NKG2A inhibition, supports this hypothesis.92,93 However, the lower 
frequency of NKG2A+ NK cells following infection by CMV, especially by strains with UL40-
encoded strongly interacting peptide, could indirectly favor an improved lysis of leukemia 
cells by NK cells. Induction of adaptive NK cells by CMV itself could lead to higher 
functional capacities and better protection from infection and relapse. 
In a study of Bjorklund et al.68, it was shown that the induction of adaptive NK cells by CMV 
reactivation has been associated with a worse clinical outcome after alloHSCT. In contrast 
to our study, they obtained the patient samples for FACS analysis at 9-12 months after 
transplantation, while we have used samples from earlier time points. Patients with early 
relapse and death were thus not included in their study. Furthermore, they included all 
patients with at least donor or recipient positive CMV serostatus in their analysis, while we 
analyzed the NK cell phenotype inside the patients with detectable CMV reactivation and 
used patients with CMV R-/D- serostatus as controls. We also used a strategy to analyze 
the phenotype and predominantly concentrated on the NKG2C mediated effects, while 
Bjorklund et al. used a cluster analysis with different markers of the whole NK cell 
population, including the expression of educating KIRs. 
Taken together, our data suggests that it could be valuable to further validate the 
correlation between NK cell repertoire shaping by infection with different HCMV strains and 
clinical outcome of alloHSCT patients. Developing strategies aiming at manipulating the 








4.7 Correlation between low viral titer and adaptive NK cells 
 
Even though the induction of adaptive NK cells by CMV is well-established, the role of 
those NK cells in the control of CMV remains to be further elucidated.  
A very recent prospective study by Redondo-Pachon et al.94 showed a significantly lower 
rate of CMV reactivation in kidney transplant recipients which had a higher amount of 
NKG2C+ NK cells before transplantation. 
In our study, however, we did not investigate the properties of NK cells before the CMV 
reactivation to look for a protection, but investigated the NK cell phenotype after 
reactivation. Based on the data from Bjorklund et al.68, which showed a stronger increase 
of NKG2C+ NK cells in patients with a more severe CMV reactivation, we expected such a 
dose effect of CMV in the induction of adaptive NK cells and consequently a correlation of 
a higher viral load with more adaptive NK cells after reactivation. Surprisingly, after 
excluding patients who were not monitored regularly by CMV PCR, we found the exact 
opposite, with more adaptive NK cells after CMV reactivation being associated with a lower 
viral load. When looking closely at the data from Bjorklund et al.68, the stronger increase of 
NKG2C+ NK cells in patients with complicated CMV reactivation is mainly driven by a low 
frequency of such cells within the donor before transplantation and thus it does not 
contradict our findings. 
Even though the correlation between a higher frequency of adaptive NK cells after CMV 
reactivation and a lower viral load does not prove any causal relationship, it is tempting to 
speculate that patients with a robust NK cell expansion were able to better control the CMV 
reactivation. We did not analyze the donor NK cells before transplantation and, because of 
low cell numbers, we did not have a chance to look at the recipient NK cells before 
reactivation. It is thus difficult to say if the transplanted NK cells13 or the expansion inside 
the host contributed to the viral control. One interesting fact is that one patient with the 
strongly interacting peptide had a lower frequency of NKG2C+ NK cells and was still able 
to control the CMV reactivation.  
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Taken together, the lack of prospective data and also the concurrent antiviral treatment 
makes it difficult to use this data supporting the clinical role of NK cells in viral control, as 
previously suggested by Redondo-Pachon et al.94. 
 
4.8 Discussion of Hypothesis 
 
We hypothesized that different CMV strains would have an influence on the properties of 
adaptive NK cells in an in vivo setting. Our data supports this hypothesis, as we found 
phenotypic differences of NK cells depending on the interaction potential of the CMV UL40-
encoded peptide. Despite the low patient number analyzed and the low frequency of 
certain CMV strains, we were able to find some indications on the influence of viral control 
and improved clinical outcome.  
Taken together, our study showed for the first time the influence of different CMV strains on 
the NK cell repertoire in alloHSCT patients.  Upon validation in a larger cohort of patients, 
this finding could signal a clinical impact in patients undergoing alloHSCT. 
Finally, one could speculate about possible therapeutic concepts derived from the data 
obtained. The strong reaction of some NK cells to certain peptides could be used for in 
vitro expansion of adaptive NK cells, which could then be used in a cell-based therapy, 
either for viral or leukemia control. 
Another idea would be to use peptides or peptide-derived complexes in a vaccination 
strategy to expand adaptive NK cells in vivo, which also could possibly lead to a better 
control of CMV or leukemia. 
Taken together, this work provides a solid starting point for further questions to be asked, 
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